In a patient with severe urosepsis, markedly elevated procalcitonin and leukocytosis who is not responding to piperacillin‑tazobactam, would a regimen of ceftazidime‑avibactam combined with aztreonam be an appropriate treatment option?

Ceftazidime-Avibactam Plus Aztreonam for Severe Urosepsis

Yes, ceftazidime-avibactam combined with aztreonam is an appropriate and potentially life-saving option for this patient with severe urosepsis not responding to piperacillin-tazobactam, particularly if carbapenem-resistant Enterobacterales (CRE) or metallo-β-lactamase (MBL)-producing organisms are suspected.

Clinical Rationale

This patient's failure to respond to piperacillin-tazobactam with markedly elevated inflammatory markers strongly suggests infection with a resistant organism, most likely CRE. The combination of ceftazidime-avibactam plus aztreonam is specifically recommended for this scenario.

Guideline Support

The 2023 guidelines for carbapenem-resistant Gram-negative bacilli explicitly recommend ceftazidime-avibactam combined with aztreonam as a preferential choice for infections caused by metallo-β-lactamases-producing CRE 1. While this is a weak recommendation with very low-quality evidence, the mortality benefit is substantial:

• 30-day mortality: 19.2% vs. 44% with other active antimicrobials (p = 0.007)
• Hazard ratio for mortality: 0.37 (95% CI 0.13-0.74)
• Clinical treatment failure rate reduced by 70% (HR: 0.30,95% CI 0.14-0.65)
• Shorter hospital length of stay (HR: 0.49) 1

Why This Combination Works

Mechanistic advantage: Aztreonam is not hydrolyzed by metallo-β-lactamases (NDM, VIM, IMP types), while ceftazidime-avibactam protects aztreonam from other β-lactamases and shows excellent synergy against both KPC-producing and NDM-producing organisms 1, 2. This dual mechanism provides coverage regardless of whether the organism produces KPC, OXA-48, or MBL enzymes.

Treatment Algorithm for This Patient

Immediate Actions:

1. Obtain blood and urine cultures immediately before escalating therapy
2. Initiate ceftazidime-avibactam 2.5g IV every 8 hours PLUS aztreonam 2g IV every 8 hours (adjust for renal function)
3. Request carbapenemase testing or whole genome sequencing if available to identify resistance mechanism 1

Coverage Spectrum:

• KPC-producing CRE: Nearly 100% susceptible to ceftazidime-avibactam alone 1
• MBL-producing CRE (NDM, VIM, IMP): Requires the addition of aztreonam for optimal activity 1, 2
• OXA-48-producing CRE: Covered by ceftazidime-avibactam 1
• ESBL-producing organisms: Excellent coverage 3

Recent Evidence in Urosepsis

A 2025 study in immunosuppressed patients with carbapenemase-producing Enterobacterales infections (including urinary sources) demonstrated:

• 7-day clinical response: 88.6-92.1% with ceftazidime-avibactam ± aztreonam
• 30-day infection-related mortality: only 2.6-13.6% 4

Critical Caveats

When to Use the Combination vs. Monotherapy:

• Use ceftazidime-avibactam ALONE if KPC or OXA-48 is confirmed
• Add aztreonam if MBL is suspected or confirmed, or if empiric coverage is needed before resistance mechanism is known 1
• Consider adding an aminoglycoside (amikacin or plazomicin) for severe infections to reduce bacterial turbidity and prevent filamentous cell formation 5

Safety Considerations:

Both agents are FDA-approved for complicated urinary tract infections and septicemia 6. The combination has demonstrated:

• Low adverse event rates 1
• No significant nephrotoxicity compared to polymyxin-based regimens 1
• Rare cross-reactivity with other β-lactams, though caution is warranted in patients with severe β-lactam allergies 6

Common Pitfalls to Avoid:

1. Don't delay escalation: Waiting for culture results in a non-responding septic patient increases mortality risk
2. Don't use aztreonam alone: It will be rapidly hydrolyzed by other β-lactamases without avibactam protection 2
3. Don't assume ceftazidime-avibactam covers everything: MBL-producers require aztreonam addition (23.5% of carbapenemases in recent US data were metallo-β-lactamases) 7
4. Adjust for renal function: Both agents require dose adjustment in renal impairment

Duration and De-escalation

Per EAU 2024 guidelines for complicated UTI with systemic symptoms, treat for 7-14 days (14 days for males when prostatitis cannot be excluded) 8. Once the patient is:

• Hemodynamically stable
• Afebrile for ≥48 hours
• Culture results available with susceptibilities

De-escalate to targeted therapy based on final susceptibility results and identified resistance mechanism 8, 1.

Alternative if Combination Unavailable:

If ceftazidime-avibactam is unavailable, aztreonam plus amoxicillin-clavulanate showed 50% susceptibility restoration for MBL-producing Enterobacterales and is markedly cheaper, though less potent 2. However, given the severity of this patient's presentation, the superior combination should be prioritized.

Bottom line: The combination is justified by the patient's clinical deterioration, high inflammatory markers, and the substantial mortality reduction demonstrated in guideline-cited studies, despite the low quality of evidence. The risk of untreated resistant infection far outweighs the cost and potential adverse effects of this regimen.